SB 1625 requires the Oklahoma Insurance Department to conduct a detailed impact analysis for any new law that would mandate changes to health insurance coverage (like adding specific treatments or requiring prior authorization). The analysis must evaluate social impact (public health benefits and affected populations), medical effectiveness (scientific evidence), and financial effects (premium changes and market stability) before such bills can be voted on. The department may hire outside experts for this analysis and must make the reports publicly available online. The bill takes effect November 1, 2026.
SB 1646 requires Oklahoma health insurance plans to cover medically necessary mental health and substance use disorder treatment without arbitrary limits, affecting all residents with such coverage. It mandates coverage for "core treatments" aligned with clinical standards (like those from psychiatric associations), prohibits limiting care to short-term/acute settings, and bans insurers from rescinding authorizations after services are provided. The bill also requires insurers to follow specific rules for reviewing treatment requests and ensures out-of-network care access when in-network options aren't available. This applies to all health benefit plans covering hospital or medical services in Oklahoma, aiming to align mental health coverage with physical health benefits. The bill is pending in committee as of February 2026.
This bill authorizes an emergency appropriation of approximately $19.66 million to the Oklahoma Department of Mental Health and Substance Abuse Services. The funds must come from the Rate Preservation Fund in the State Treasury and are designated specifically for Title XIX services, which are Medicaid-funded mental health and substance abuse programs. The legislation includes an emergency provision, allowing the funding to take effect immediately upon the governor's approval without waiting for the regular budget cycle. This action provides direct financial resources to the state agency responsible for administering mental health and substance abuse services.
SB 207 establishes the Oklahoma Rare Disease Advisory Council within the State Department of Health to address the needs of Oklahomans living with rare diseases (defined as conditions affecting fewer than 200,000 people nationally). The Council, composed of 13 diverse members including patients, caregivers, healthcare providers, researchers, and industry representatives, will conduct public hearings, develop policy recommendations, and create emergency care protocols to improve access to specialists, diagnostics, and equitable treatment. The bill also modifies Oklahoma’s newborn screening program to require an educational initiative for treatable genetic disorders, aiming to prevent intellectual disabilities and reduce infant mortality through early intervention. This legislation directly affects rare disease patients, their families, healthcare providers, and state agencies responsible for public health programs in Oklahoma.
HB 2513, titled the "Oklahoma Mental Health Reform Act of 2025," proposed creating a position requiring an individual with specific qualifications to address the Department of Mental Health and Substance Abuse Services' court-ordered consent decree. The bill specified requirements for this appointee and included an emergency provision. It was scheduled to take effect November 1, 2025, but was pocket-vetoed by the Governor on May 30, 2025, with the veto taking effect June 15, 2025, meaning it never became law. The bill directly affected the Department's compliance with its existing legal agreement but was not enacted.
HB 2645 creates a tax credit for qualifying doctors practicing medicine in rural Oklahoma, directly affecting licensed physicians who meet specific residency and education criteria. The credit, capped at $20,000 per year per doctor, applies to taxable income from medical practice in designated rural areas (population under 25,000 and at least 25 miles from larger cities). The bill includes an annual $1 million total credit limit, with adjustments to prevent exceeding this cap. The bill was pocket-vetoed by the governor on June 15, 2025, and never became law.
HB 2262 requires nursing homes, assisted living facilities, and other care providers marketing specialized dementia care to publicly disclose detailed information about their services. Facilities must submit a standardized form to Oklahoma's State Department of Health, covering staff ratios, care plans, facility design, activities, fees, and family involvement - ensuring transparency for residents and families considering placement. The bill mandates posting this disclosure online and in facilities, with the Department reviewing it during inspections. It directly affects dementia care providers and supports informed decisions by families seeking appropriate care.
HB 1576 requires Oklahoma Medicaid to cover rapid whole genome sequencing (RWGS) for eligible beneficiaries under age 21 with complex or acute illnesses of unknown cause while receiving critical care in a hospital. It mandates coverage only when specific medical criteria are met, such as symptoms suggesting broad genetic testing needs, timely diagnosis being critical for treatment, and conditions like congenital anomalies or abnormal test results. The bill also ensures genetic data used for diagnosis is protected under HIPAA, allows research use only with explicit patient or guardian consent (with opt-out rights), and requires the Oklahoma Health Care Authority to implement rules and seek federal approval for coverage. This policy directly affects Medicaid-covered children and teens in intensive care with undiagnosed conditions.
HB 2298 allows qualified Advanced Practice Registered Nurses (APRNs) in Oklahoma - such as nurse practitioners and nurse-midwives - to prescribe medications independently after meeting specific requirements. To qualify, APRNs must complete 6,240 supervised clinical hours, hold a valid license, and carry $1 million in malpractice insurance per incident. The bill also sets rules for APRN advertising (requiring clear disclosure of their role and scope) and defines supervision requirements for those not yet eligible for independent prescribing. It modifies Oklahoma’s Nursing Practice Act, Pharmacy Act, and Controlled Substances Act to implement these changes.
HB 2584 allows physician assistants (PAs) in Oklahoma to prescribe and administer certain controlled substances under the supervision of a licensed physician, as specified in the Oklahoma Pharmacy Act and Physician Assistant Act. The bill clarifies that pharmacists may dispense these prescriptions only when written by a PA licensed in Oklahoma and supervised by an Oklahoma-licensed physician, and it modifies requirements for practice agreements between PAs and their supervising physicians. It also creates a 9-member Physician Assistant Committee with specific membership rules to oversee PA licensure and practice standards. The law directly affects PAs, supervising physicians, and pharmacists who dispense controlled substances. (Summary based on bill text amendments to Sections 353.1a, 519.2, and 519.3 of Oklahoma statutes.)
